Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : SAKK
Deal Size : Undisclosed
Deal Type : Collaboration
Intensity Therapeutics, Sakk Ink Agreement for Phase 2 Trial in Early-Stage Cancer
Details : The collaboration aims to conduct a phase 2 trial evaluating the clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 13, 2024
Lead Product(s) : Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : SAKK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 18, 2023
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2023
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : The Benchmark Company
Deal Size : $19.5 million
Deal Type : Public Offering
Details : The company intends to use the net proceeds for the development of INT230-6, a formulation consisting of its proprietary amphiphilic cell penetration enhancer molecule, 8-((2-hydroxybenzoyl)amino)octanoate, also referred to as SHAO, combined with cisplat...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 30, 2023
Lead Product(s) : 2-hydroxybenzoyl Amino Octanoate,Vinblastine Sulfate,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : The Benchmark Company
Deal Size : $19.5 million
Deal Type : Public Offering
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Takeda Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, MMAE, utilizing Seagen's proprietary technology,for the treatment of...
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 14, 2023
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Takeda Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ADCETRIS (brentuximab vedotin), is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of cHL and expressed on the surface of several types of lymphomas. It is approved in seven indications in the U.S.
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 12, 2022
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INT230-6 is designed for direct intratumoral injection, composed of two proven, potent anti-cancer agent, cisplatin and vinblastine, and penetration enhancer molecule that help disperse potent cytotoxic drugs throughout tumors for diffusion into cancer c...
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2022
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial showed ADCETRIS (brentuximab vedotin) in combination with standard of care dose-intensive chemotherapy AVE-PC achieved superior event-free survival (EFS) compared to the current standard of care for the pediatric dose-intensive regimen of ABVE-...
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 03, 2022
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data show INT230-6 (Cisplatin), is designed for direct intratumoral injection is well tolerated and elicits both direct tumor killing and immune activating effects in a variety of solid tumors.
Brand Name : INT230-6
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2022
Lead Product(s) : Cisplatin,Vinblastine Sulfate,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Seagen
Deal Size : Not Applicable
Deal Type : Not Applicable
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
Details : ADCETRIS (Brentuximab Vedotin), is indicated for the treatment of adult patients with untreated Stage III/IV classical Hodgkin lymphoma in combination with AVD in the U.S and for the treatment of adult patients with previously untreated CD30-positive Sta...
Brand Name : Adcetris
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Seagen
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?